期刊文献+

阿昔洛韦2/3水合物的制备和表征 被引量:3

Preparation and characterization of acyclovir 2/3 hydrate
原文传递
导出
摘要 目的:建立阿昔洛韦2/3水合物的制备方法和完整的晶型表征分析方法。方法:在水中重结晶制备阿昔洛韦2/3水合物,并采用衰减全反射红外和红外吸收光谱、差示扫描量热分析、热重分析、粉末和单晶X-射线衍射法对该晶型进行全面的表征。结果:获得了阿昔洛韦2/3水合物晶型制备和表征方法,得到了傅立叶衰减全反射红外光谱和热重分析谱图,通过热分析法探明了阿昔洛韦2/3水合物向无水晶型转化和无水晶型间转化的过程及其对应的热效应,5.18%的失重率对应于2/3结晶水。结论:所建立的晶型制备方法简便,阿昔洛韦2/3水合物晶型表征方法可靠,数据全面。 Objective: To establish the methods for preparation and characterization of acyclovir 2/3 hydrate. Meth- ods : Acyclovir 2/3 hydrate was obtained by re - crystallization using water as the solvent and was comprehensively characterized by infrared spectroscopy, differential scanning calorimetry ( DSC ), thermogravimetry analysis ( TGA ), and X - ray diffraction. Results: The preparation and characterization method for the crystal form of acyclovir 2/3 hydrate was achieved. The attenuated total reflectance fourier transform infrared spectrum( ATR -FT -IR) and the TGA spectrum were reported for the first time. In thermal analysis, the thermal events of transformation from hydrate to anhydrous form were demonstrated and the weight loss of 5.18% observed in the TGA curve was equivalent to the stoichiometric water content in aeyclovir 2/3 hydrate. Conclusion: The established crystal preparation method is simple, and the characterization method for the acyclovir 2/3 hydrate crystal is reliable with sufficient data.
出处 《药物分析杂志》 CAS CSCD 北大核心 2013年第9期1636-1639,共4页 Chinese Journal of Pharmaceutical Analysis
基金 浙江省应对技术性贸易壁垒技术攻关项目(2010357) 浙江省新产品计划项目(2008D60SA870353)
关键词 多晶型药物 阿昔洛韦2 3水合物 衰减全反射红外光谱 红外吸收光谱 差示扫描量热分析 热重分析 X-射线衍射 polymorphic drug acyclovir 2/3 hydrate attenuated total reflection infrared spectroscopy infrared spec- troscopy differential scanning calorimetry thermogravimetry analysis X - ray diffractometry
  • 相关文献

参考文献21

  • 1Brittain HG.Polymorphism in Pharmaceutical Solids.New York:Marcel Dekker,1999.
  • 2SU De-sen(苏德森),WANG Si-ling(王思玲).Physical Pharmaceutics(物理药剂学).Beijing(北京):Chemical Industry Press(化学工业出版社),2004.7.
  • 3Haledlian J,McCrone W.Pharmaceutical applications of polymorphism.J Pharm Sci,1969,58(8):911.
  • 4Tedesco E,Giron D,Pfeffer S.Crystal structure elucidation and morphology study of pharmaceuticals in development.Cryst Eng Comm,2002,4(67):393.
  • 5Vippagunta SR,Brittain HG,Grant DJW.Crystalline solids.Adv Drug Deliv Rev,2001,48(1):3.
  • 6O'Brien JJ,Campoli-Richards DM.Acyclovir-an updated review of its antiviral activity,pharmacokinetic properties and therapeutic efficacy.Drugs,1989,37(3):233.
  • 7Prentice HG,Gluckman E,Powles RL,et al.Impact of long-term acyclovir on cytomegalovirus-infection and survival after allogeneic bone-marrow transplantation.Lancet,1994,343(8900):749.
  • 8Balfour HH,Chace BA,Stapleton JT,et al.A randomized,placebo-controlled trial of oral acyclovir for the prevention of cytomegalo-virus disease in recipients of renal-allografts.Engl J Med,1989,320(21):1381.
  • 9Birnbaum GI,Cygler M,Shugar D.Conformational features of acyclonucleosides:structure of acyclovir,an antiherpes agent.Can J Chem,1984,62(12):2646.
  • 10Birnbaum GI,Cygler M,Kusmierek JT,et al.Structure and conformation of the potent anti-herpes agent 9-(2-hydroxyethoxymethyl) guanine (acycloguanosine).Biochem Biophys Res Commun,1981,103(3):968.

二级参考文献55

共引文献69

同被引文献53

  • 1冒莉,郑启泰,吕扬.固体药物多晶型的研究进展[J].天然产物研究与开发,2005,17(3):371-375. 被引量:48
  • 2杨继章,刘瑞琴,杨树民,昝淑红.注射用加替沙星与注射用阿昔洛韦配伍的稳定性考察及其红外光谱分析[J].中国药房,2006,17(14):1101-1103. 被引量:13
  • 3宁黎丽.对药物研究中晶型问题的几点思考[J].药品评价,2007,4(4):304-306. 被引量:6
  • 4ChP 2010.Vol Ⅱ(中国药典2010年版.二部)[S].2010:704.
  • 5SKOULIKA SG,GEORGIOU CA. Rapid,noninvasive quantitative determination of acyclovir in pharmaceutical solid dosage forms through their poly(vinyl chloride)blister package by solid-state Fourier transform raman spectroscopy[J].Appl Spectrosc,2003,57(4):407.
  • 6AMIN A,BOURGET P,VIDAL F,et al. Routine application of Raman spectroscopy in the quality control of hospital compounded ganciclovir[J]. Int J Pharm,2014,474(1/2):193.
  • 7ZHANG Q,LU L,DAI W,et al.Polymorphism and isomorphism of huperzine A solvates:structure,properties and form transformation[J].Crystengcomm,2014,16(10):1919.
  • 8WANG JR,WANG X,LU L,et al.Highly crystalline forms of valsartan with superior physicochemical stability[J].Cryst Growth Design,2013,13(7):3261.
  • 9MA S,LIU H,JIAO H,et al.Neuroprotective effect of ginkgolide K on glutamate-induced cytotoxicity in PC 12 cells via inhibition of ROS generation and Ca(2+) influx[J].Neurotoxicology,2012,33(1):59.
  • 10MA S,LIU X,XUN Q,et al.Neuroprotective effect of ginkgolide K against H2O2-induced PC12 cell cytotoxicity by ameliorating mitochondrial dysfunction and oxidative stress[J].Biol Pharm Bull, 2014,37(2):217.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部